Pacira BioSciences, Inc. (PCRX) stock
PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)
Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –
Pacira BioSciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Pacira BioSciences's operating cash flow for the twelve months ending Jun 30, 2026 was $187.66M, up 39.5% year over year. For fiscal 2025 it was $151.99M, down 19.7% from the year before. Over ten years it grew 18.4% a year on average. The highest annual figure on record is $189.39M in fiscal 2024.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $151.99M | -19.7% |
| FY2024 | Dec 31, 2024 | $189.39M | +22.5% |
| FY2023 | Dec 31, 2023 | $154.65M | +6.5% |
| FY2022 | Dec 31, 2022 | $145.27M | +15.6% |
| FY2021 | Dec 31, 2021 | $125.72M | +63.2% |
| FY2020 | Dec 31, 2020 | $77.03M | +9.2% |
| FY2019 | Dec 31, 2019 | $70.52M | +44.3% |
| FY2018 | Dec 31, 2018 | $48.87M | +174.8% |
| FY2017 | Dec 31, 2017 | $17.79M | -46.8% |
| FY2016 | Dec 31, 2016 | $33.45M | +19.4% |
| FY2015 | Dec 31, 2015 | $28.02M | +5.5% |
| FY2014 | Dec 31, 2014 | $26.56M | – |
| FY2013 | Dec 31, 2013 | -$43.84M | – |
| FY2012 | Dec 31, 2012 | -$70.13M | – |
| FY2011 | Dec 31, 2011 | -$31.00M | – |
| FY2010 | Dec 31, 2010 | -$24.88M | – |
| FY2009 | Dec 31, 2009 | -$20.84M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $57.46M | +378.4% |
| Q1 FY2026 | Mar 31, 2026 | $25.68M | -27.6% |
| Q4 FY2025 | Dec 31, 2025 | $43.69M | +31.9% |
| Q3 FY2025 | Sep 30, 2025 | $60.83M | +12.8% |
| Q2 FY2025 | Jun 30, 2025 | $12.01M | -77.4% |
| Q1 FY2025 | Mar 31, 2025 | $35.46M | -27.8% |
| Q4 FY2024 | Dec 31, 2024 | $33.13M | -30.4% |
| Q3 FY2024 | Sep 30, 2024 | $53.92M | +21.3% |
| Q2 FY2024 | Jun 30, 2024 | $53.24M | +22.4% |
| Q1 FY2024 | Mar 31, 2024 | $49.10M | +156.7% |
| Q4 FY2023 | Dec 31, 2023 | $47.58M | +13.2% |
| Q3 FY2023 | Sep 30, 2023 | $44.44M | +4.2% |
| Q2 FY2023 | Jun 30, 2023 | $43.50M | +45.9% |
| Q1 FY2023 | Mar 31, 2023 | $19.13M | -37.8% |
| Q4 FY2022 | Dec 31, 2022 | $42.04M | +81.1% |
| Q3 FY2022 | Sep 30, 2022 | $42.65M | -29.2% |
| Q2 FY2022 | Jun 30, 2022 | $29.81M | -1.1% |
| Q1 FY2022 | Mar 31, 2022 | $30.78M | +154.8% |
| Q4 FY2021 | Dec 31, 2021 | $23.22M | -50.3% |
| Q3 FY2021 | Sep 30, 2021 | $60.29M | +51.5% |
| Q2 FY2021 | Jun 30, 2021 | $30.13M | – |
| Q1 FY2021 | Mar 31, 2021 | $12.08M | +94.6% |
| Q4 FY2020 | Dec 31, 2020 | $46.67M | +80.2% |
| Q3 FY2020 | Sep 30, 2020 | $39.78M | +116.7% |
| Q2 FY2020 | Jun 30, 2020 | -$15.62M | -168.6% |
| Q1 FY2020 | Mar 31, 2020 | $6.21M | +77.4% |
| Q4 FY2019 | Dec 31, 2019 | $25.90M | +22.1% |
| Q3 FY2019 | Sep 30, 2019 | $18.35M | +10.4% |
| Q2 FY2019 | Jun 30, 2019 | $22.76M | +66.0% |
| Q1 FY2019 | Mar 31, 2019 | $3.50M | – |
| Q4 FY2018 | Dec 31, 2018 | $21.22M | +25.3% |
| Q3 FY2018 | Sep 30, 2018 | $16.63M | – |
| Q2 FY2018 | Jun 30, 2018 | $13.71M | +275.0% |
| Q1 FY2018 | Mar 31, 2018 | -$2.69M | -44916.7% |
| Q4 FY2017 | Dec 31, 2017 | $16.93M | -2.4% |
| Q3 FY2017 | Sep 30, 2017 | -$2.81M | -124.0% |
| Q2 FY2017 | Jun 30, 2017 | $3.66M | – |
| Q1 FY2017 | Mar 31, 2017 | $6.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $17.35M | – |
| Q3 FY2016 | Sep 30, 2016 | $11.68M | – |
See a number that looks wrong?